This Medudy course is a video tutorial for physicians on the topic “Treatment of Advanced Prostate Cancer: The ARASENS Study.”
Professor Dr. Marc-Oliver Grimm, Director of the Department of Urology at Jena University Hospital, presents the key findings of the ARASENS study, which investigated a triple therapy regimen consisting of darolutamide, docetaxel, and ADT in patients with mHSPC.
Note: All "speakers" appearing in the Medudy videos are AI-based avatars used to improve the didactics of the videos. The people on whom the avatars are based have explicitly consented to their use. All content is based on high-quality scientific sources and is created and reviewed by the Medudy medical team.
The course was developed with the kind support of Bayer.
By the end of this course, you will know:
- The design and rationale of the ARASENS study investigating triple therapy (darolutamide + ADT + docetaxel) in metastatic hormone-sensitive prostate cancer (mHSPC).
- the significant benefits of darolutamide triple therapy in terms of overall survival (OS) and other secondary endpoints.
- the results of the subgroup analyses (e.g., by disease burden and age), as well as the therapy’s favorable safety and quality-of-life profile.
- the positioning of darolutamide triple therapy in current treatment guidelines (S3 Guideline on Prostate Cancer).
